TTNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TTNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.240. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-807.16 for the trailing ten years ended in Mar. 2024.
During the past 3 years, the average E10 Growth Rate was 24.40% per year. During the past 5 years, the average E10 Growth Rate was 21.90% per year. During the past 10 years, the average E10 Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
During the past 13 years, the highest 3-Year average E10 Growth Rate of Titan Pharmaceuticals was 30.80% per year. The lowest was 4.50% per year. And the median was 16.50% per year.
As of today (2024-05-28), Titan Pharmaceuticals's current stock price is $6.4173. Titan Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-807.16. Titan Pharmaceuticals's Shiller PE Ratio of today is .
The historical data trend for Titan Pharmaceuticals's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
E10 | Get a 7-Day Free Trial | -2,161.34 | -1,953.94 | -1,370.57 | -716.59 | -844.01 |
Titan Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
E10 | Get a 7-Day Free Trial | -913.31 | -900.36 | -882.28 | -844.01 | -807.16 |
For the Biotechnology subindustry, Titan Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -1.24 | / | 131.7762 | * | 131.7762 | |
= | -1.240 |
Current CPI (Mar. 2024) = 131.7762.
Titan Pharmaceuticals Quarterly Data
per share eps | CPI | Adj_EPS | |
201406 | -198.002 | 100.560 | -259.468 |
201409 | -180.001 | 100.428 | -236.188 |
201412 | -216.002 | 99.070 | -287.312 |
201503 | -864.007 | 99.621 | -1,142.886 |
201506 | -396.003 | 100.684 | -518.293 |
201509 | -324.003 | 100.392 | -425.294 |
201512 | -396.003 | 99.792 | -522.923 |
201603 | -324.003 | 100.470 | -424.960 |
201606 | 1,980.020 | 101.688 | 2,565.880 |
201609 | -432.003 | 101.861 | -558.876 |
201612 | -539.860 | 101.863 | -698.398 |
201703 | -576.005 | 102.862 | -737.917 |
201706 | -612.005 | 103.349 | -780.342 |
201709 | -720.006 | 104.136 | -911.116 |
201712 | -630.491 | 104.011 | -798.797 |
201803 | -444.004 | 105.290 | -555.698 |
201806 | -150.001 | 106.317 | -185.921 |
201809 | -408.004 | 106.507 | -504.806 |
201812 | -161.601 | 105.998 | -200.902 |
201903 | -204.002 | 107.251 | -250.653 |
201906 | -228.002 | 108.070 | -278.018 |
201909 | -108.001 | 108.329 | -131.377 |
201912 | -41.211 | 108.420 | -50.089 |
202003 | -40.600 | 108.902 | -49.128 |
202006 | -29.200 | 108.767 | -35.377 |
202009 | -30.400 | 109.815 | -36.480 |
202012 | -8.643 | 109.897 | -10.364 |
202103 | -5.600 | 111.754 | -6.603 |
202106 | -3.400 | 114.631 | -3.909 |
202109 | -3.800 | 115.734 | -4.327 |
202112 | -5.200 | 117.630 | -5.825 |
202203 | -4.800 | 121.301 | -5.215 |
202206 | -3.600 | 125.017 | -3.795 |
202209 | -3.600 | 125.227 | -3.788 |
202212 | -3.390 | 125.222 | -3.567 |
202303 | -2.230 | 127.348 | -2.308 |
202306 | -2.200 | 128.729 | -2.252 |
202309 | -0.400 | 129.860 | -0.406 |
202312 | -2.610 | 129.419 | -2.658 |
202403 | -1.240 | 131.776 | -1.240 |
Add all the adjusted EPS together and divide 10 will get our e10.
Titan Pharmaceuticals (NAS:TTNP) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Titan Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Seow Gim Shen | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
Sire Group Ltd. | 10 percent owner | NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Matthew Charles Mcmurdo | director | 1047 SEWARD AVE., WESTFIELD NJ 07090 |
Peter Louis Chasey | director | 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129 |
Eric Howard Greenberg | director | 710 CARLYLE ST, WOODMERE NY 11598 |
Avraham Ben-tzvi | director | 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544 |
Katherine Beebe | director, officer: President and COO | 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
Choon Hau Choong | 10 percent owner | NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060 |
David E. Lazar | director, 10 percent owner, officer: Chief Executive Officer | VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000 |
Activist Investing Llc | other: Member of 10% owner group | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036 |
Joseph A Akers | director | 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111 |
James R Mcnab | director | C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Marc Rubin | director, officer: Executive Chairman | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Dane Hallberg | officer: See Remarks | 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Value_Insider Value_Insider • 12-15-2022
By GuruFocus Research GuruFocus Editor • 01-27-2023
By Marketwired • 10-16-2023
By Value_Insider Value_Insider • 12-12-2022
By PRNewswire PRNewswire • 11-30-2020
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocus Research • 06-24-2023
By GuruFocusNews GuruFocusNews • 06-20-2022
By PRNewswire PRNewswire • 07-05-2022
By GuruFocusNews GuruFocusNews • 07-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.